SECURITIES AND EXCHANGE COMMISSION
 WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report: August 9, 2005

BioCryst Pharmaceuticals, Inc.
 (Exact Name of Registrant as Specified in Charter)

Delaware

 

000-23186

 

62-1413174

(State or other jurisdiction

 

(Commission

 

(IRS Employer

of incorporation)

 

File Number)

 

Identification #)

2190 Parkway Lake Drive, Birmingham, Alabama 35244
(Address of Principal Executive Office)

(205) 444-4600
(Registrant’s telephone number, including area code)


Item 8.01 Other Events.

          On August 9, 2005, Registrant issued a press release announcing the initiation of a Phase I pharmacokinetic clinical trial with intravenous/oral Fodosine™ in healthy volunteers. The press release is being filed as Exhibit 99.1 to this Current Report on Form 8-K.

          Neither the filing of any press release as an exhibit to this Current Report on Form 8-K nor the inclusion in such press release of a reference to Registrant’s Internet address shall, under any circumstances, be deemed to incorporate the information available at such Internet address into this Current Report on Form 8-K.  The information available at Registrant’s Internet address is not part of this Current Report on Form 8-K or any other report filed by Registrant with the Securities and Exchange Commission.

Item 9.01 Exhibits.

 

Exhibit No.

 

Description

 

 

 

99.1

 

Press release dated August 9, 2005 entitled “BioCryst Advances Lead Product Program; Initiates Intravenous/Oral Pharmacokinetic Clinical Trial of Fodosine™ in Healthy Volunteers to Support Pivotal Trial”.

SIGNATURES

          Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 9, 2005

BIOCRYST PHARMACEUTICALS, INC.

 

 

 

 

By:

/s/ MICHAEL A. DARWIN

 

 

 

 

Michael A. Darwin

 

 

Chief Financial Officer and Chief

 

 

Accounting Officer

EXHIBIT INDEX

 

Exhibit No.

 

Description

 

 

 

99.1

 

Press release dated August 9, 2005 entitled “BioCryst Advances Lead Product Program; Initiates Intravenous/Oral Pharmacokinetic Clinical Trial of Fodosine™ in Healthy Volunteers to Support Pivotal Trial”.